��ժҪ��Ϣ

[an error occurred while processing this directive]

��Ƥ��Բ�ѧ��־ 2002, 28(3) 162-166 DOI: ISSN: 2096-5540 CN: 32-1880/R

��Ŀ¼ | ��Ŀ¼ | �� | �߼�� [��ӡ��ҳ] [�ر�]

��

	��չ��

	��Ϣ
	Supporting info
	PDFȫ��
	[HTMLȫ��]
	�ο��
	��뷴��
	�ѱ��Ƽ��
	��ҵ��
	��ù��
	��ñ��
	Email Alert
	��·��
	��Ϣ
	��Ĺؼ��
	��Ǵ�
	ϵͳ��
	DNAø��
	ȱ��
	��
	��չ
	��
	PubMed
	Article by
	Article by

DNAø��ȱ��SLE��Ե��о��չ

��չ, ��

��ɽҽ�ƴ�ѧ��ɼ��ҽԺƤ�� 510120

ժҪ��

ϵͳ�Ժ��Ǵ��Ĳ��,��δ��ȫ��,�о��DNA�˵��ϵͳ�Ժ��Ǵ��Ҫ��,��DNAøI��л��Ҫ��ø.��˹��DNAøIȱ��ϵͳ�Ժ��Ǵ��п��ܵ��²��,Ϊ��һ��о�ϵͳ�Ժ��Ǵ��Ĳ��ṩһ��˼·.

�ؼ���� Ǵ� ϵͳ�� DNAø�� ȱ��

Abstract:

Keywords:

�ո�� 2001-10-11 �޻�� ��淢��

DOI:

��Ŀ:

ͨѶ��:

��߼��:

�ο��ף�

[1] Berden JH,Licht R,van Bruggen MC,et al.Role of nucleosomes for induction and glomerular binding of autoantibodies in lupus nephritis.Curt Opin Nephrol Hypertens,1999,8(3):299-306.
[2] Lacks SA.Deoxyribonuclease �� in mammalian tissues.Specificity of inhi-bition by actin.J Biol Chem,1981,256(6):2644-2648.
[3] Chitrabammng S,Rubin RL,Tan EM.Serum deoxyribonuclease �� and clinical activity in systemic lupus erythematosus.Rheumatol Int,1981,1(2):55-60.
[4] Macanovic M,Lachmann PJ.Measurement of deoxyribonuclease ��(DNase) in the serum and urine of systemic lupus erythematesus(SLE)-prone NZB/NZW mice by a new radial enzyme diffusian assay.Clin Exp Immunol,1997,108(2):220-226.
[5] Lefkowith JB,Kiehl M,Rttbenstein J,et al.Heterogeneity and clinical significance of glomerular-binding antibodies in systemic lupus erythematosus.J Clin Invest,1996,98(6):1373-1380.
[6] TerRorg EJ,Horst G,Hummel EJ,et al.Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus.A lang-term,prospective study.Arthritis Rheum,1990,33(5):634-643.
[7] Malide D,Londono I,Russo P,et al.Ultrastructttral localization of DNA in immune deposits of human lupus nephritis.Am J Pathol,1993,143(1):304-311.
[8] Macanovic M,Sinicrepi D,Shak S,et al.The treatment of systemic lupus erythematesus(SLE) in NZB/WF1 hybrid mice; studies with recombi-nant murine DNase and with dexamethesone.Clin Exp Immunol,1996,106(2):243-252.
[9] Walport MJ.Lupus,DNase and defective disposal of cellular debris.Nat Genet,2000,25(2):135-136.
[10] Rumore PM,Steinman CR.Endogenous circulating DNA in systemic lu-pus erythematesus.Occurrence as multimeric complexes bound to histone.J Clin Invest,1990,86(1):69-74.
[11] Mohan C,Adams S,Stanik V,et al.Nucleosome:a major immunogen for pathogenic autoantibody-inducing T cells of lupus.J Exp Med,1993,177(5):1367-1381.
[12] Botto M,Dell' Agnola C,Bygrave AE,et al.Homozygous Clq deficiency causes glomemlonephritis associated with multiple apeptotic bodies.Nat Genet,1998,19(1):56-59.
[13] Bickerstaff MC,Botto M,Hutehinsan WL,et al.Serum amyloid P component controls chromatin degradation and prevents antinuclear antoimmunity.Nat Med,1999,5(6):694-697.
[14] Polzar B,Zanotti S,Stephan H,et al.Distributien of dooxyribonuclease �� in rat tissues and its correlation to cellular turnover and apoptosis(programmed cell death).Eur J Cell Biol,1994,64(1):200-210.
[15] Lachmann PJ.The in vivo destructien of antigen-a tool for probing and modulating an autoimmune response.CAin Exp Immunol,1996,106(2):187-189.
[16] Peitsch MC,Innler M,French LE,et al.Genomic organisatien and expressien of mouse deoxyribonuclease ��.Bioohern Biophys Res Commun,1995,207(1):62-68.
[17] Napirei M,Karsunky H,Zevnik B,et al.Features of systemic lupus erythematosus in Dnasel-deficient mice.Nat Genet,2000,25(2):177-181.
[18] Lazarides E,Lindberg U.Actin is the naturally occurring inhibitor of deoxyribonuclease I.Prec Nail Acad Sci U S A,1974,71(12):4742-4746.
[19] Hadjiyannaki K,Lachmann PJ.The relation of deoxyribenuclease inhibitor levels to the occurrence of antinuclear antibodies in NZB-NZW mice.Clin Exp lmmunol,1972,11(2):291-295.
[20] Ulmer JS,Herzka A,Toy KJ,et al.Engineering actin-resistsnt human DNase �� for treatment of cystic frbrosis.Proc Natl Acad Sci U S A,1996,93(16):8225-8229.
[21] Puccetti A,Madaio MP,Bellese G,et al.Anti-DNA antibodies bind to DNase ��.J Exp Med,1995,181(5):1797-1804.
[22] Shak S,Capon DJ,Hellmiss R,et al.Recombinant human DNase �� reduces the viscosity of cystic fibrosis sputum.Proc Natl Acad Sci U S A,1990,87(23):9188-9192.
[23] Davis JC Jr,Manzi S,Yarboro C,et al.Recombinant human ��Dnase ��(rhDNase) in patients with lupus nephritis.Lupus,1999,8(1):68-76.
[24] Prince WS,Baker DL,Dodge AH,et al.Pharmacodynamics of recombinant human DNase �� in serum.Clin Exp Immunol,1998,113(2):289.
[25] Pan CQ,Dodge TH,Baker DL,et al.Improved potency of hyperactive and actin-resistant human DNase �� variants for treatment of cystic fibrosis and systemic lupus erythematosus.J Biol Chem,1998,273(29):18374.

��е��

1��, ��, �˵��.��ϸ��-1��ϵͳ�Ժ��Ǵ�[J]. ��Ƥ��Բ�ѧ��־, 2007,33(6): 349-351

2��Ƽ, ��, ��ɭ, ��ѧ��.��ͯϵͳ�Ժ��Ǵ��Ľ�չ[J]. ��Ƥ��Բ�ѧ��־, 2007,33(6): 352-354

3��º��,��־��,Ϳ��ͥ.SLE�ϲ��о��չ[J]. ��Ƥ��Բ�ѧ��־, 2008,34(4): 221-223

4��,��ѧ��.��ص��Ӽ��SLE[J]. ��Ƥ��Բ�ѧ��־, 2008,34(4): 224-226

5��Ժ�÷,��,�ܻ�.��Ժ��Ǵ�һ��[J]. ��Ƥ��Բ�ѧ��־, 2008,34(4): 214-214

6��,��.ϸ��T�ܰ�ϸ��ؿ�ԭ-4��SLE[J]. ��Ƥ��Բ�ѧ��־, 2008,34(6): 382-384

7��ʢ,��.SLE B�ܰ�ϸ��ƽ�չ[J]. ��Ƥ��Բ�ѧ��־, 2009,35(2): 79-81

8��С��,��,��ٺ�.DNA�׻�ת��ø��SLE��Ŵ��е��[J]. ��Ƥ��Բ�ѧ��־, 2009,35(2): 90-92

9��ɺ ��.��Ƥ�ʼ��SLE��Ӧ�ķ��ӻ��[J]. ��Ƥ��Բ�ѧ��־, 2009,35(3): 145-147

10��³�� ֣��.ҩ��յ��Ժ��Ǵ�[J]. ��Ƥ��Բ�ѧ��־, 2009,35(5): 294-296

11�� .��Ƥ��ͺ��Ǵ��ѷ��о��չ[J]. ��Ƥ��Բ�ѧ��־, 2009,35(6): 370-372